21 March 2024 Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival Download Presentation Webcast Workbook
7 March 2024 Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial Download Presentation Webcast Workbook
31 January 2024 Scandion Oncology reports positive topline Phase IIa data from the CORIST Part 3 trial Download Presentation Webcast Workbook
5 January 2024 Scandion Oncology receives Notice of Allowance for patent to enhance US patent exclusivity on SCO-101 Download Presentation Webcast Workbook
21 November 2023 Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months Download Presentation Webcast Workbook
12 September 2023 Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer Download Presentation Webcast Workbook
18 July 2023 The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101 Download Presentation Webcast Workbook
31 March 2023 Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial) Download Presentation Webcast Workbook
1 December 2022 Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer Download Presentation Webcast Workbook
30 September 2022 Scandion Oncology announce topline results from part 2 of the CORIST phase II trial Download Presentation Webcast Workbook
31 August 2022 Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology Download Presentation Webcast Workbook
30 August 2022 Scandion Oncology announce change to its Executive Management Download Presentation Webcast Workbook